Advertisement

Topics

H7N9 Bird Flu Virus - Biotech, Pharma and Life Science Channel

19:38 EDT 20th October 2017 | BioPortfolio

Avian influenza A H7 viruses are a group of influenza viruses that normally circulate among birds. The avian influenza A(H7N9) virus is one subgroup among the larger group of H7 viruses. Although some H7 viruses (H7N2, H7N3 and H7N7) have occasionally been found to infect humans, no human infections with H7N9 viruses have been reported until recent reports from China.

News Articles [7 Associated News Articles listed on BioPortfolio]

First Weekly Subscription Service to Provide Early Warning of Coming Viral Outbreaks

BOSTON, Sept. 27, 2017 /PRNewswire/ -- Replikins, LLC., a Boston-based biotechnology research and analytics firm, today introduced the first weekly subscription service that can predict the ...

Australian Biotech Leads New Hope for Influenza Control

Australian researchers could pave the way for a new approach to influenza control with positive results presented today from preclinical studies demonstrating the effectiveness of...

$5.8 Million Awarded For Vaccine Engineering Will Use "Immune History" To Protect Against Bird Flu, A Collaboration Led By EpiVax

PROVIDENCE, R.I., Sept. 18, 2017 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") a pioneer in the fields of bioinformatics and immune engineering, today announced a new NIH-funded collaboration to develo...

S-033188 Phase 3 CAPSTONE-1 Study Results for Treatment of Influenza Presented at the European Scientific Working Group on Influenza Conference

OSAKA, Japan, Sept. 13, 2017 /PRNewswire/ -- Results of a S-033188 Phase 3 study in influenza patients (CAPSTONE-1) were released at the 6th European Scientific Working Group on Influenza Confere...

InDevR Receives NIH Support for VaxArray® Pandemic Influenza Vaccine Potency Test

New VaxArray® potency reagent kit for potential pandemic H7N9 vaccines InDevR, Inc., an innovative life science company dedicated to improving biopharmaceutical and vaccine m...

Influenza A Virus, H7N9 Subtype Infections Pipeline Review, H1 2017 [Report Updated: 27062017] Prices from USD $2000

Influenza A Virus, H7N9 Subtype Infections Pipeline Review, H1 2017SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H7N9 Subtype Infection...

Is a new flu pandemic just three mutations away?

"Just three mutations are needed to make bird flu a potential pandemic strain that could kill millions," is the alarming headline from the Mail Online. However, the chance of all three mutat...

Events [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Ansun BioPharma

Ansun BioPharma is a clinical stage biopharmaceutical company focused on the development of unique host-directed anti-viral therapies for respiratory viruses. Ansun BioPharma has ...

Clinical Trials [11 Associated Clinical Trials listed on BioPortfolio]

Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly

This is a randomized, double-blinded, Phase II study in healthy males and non-pregnant females 19 years and older that is designed to assess the safety, reactogenicity, and immunogenicity ...

Immunogenicity of Monovalent Inactivated Influenza A/H7N9 Virus Vaccine.

This is a single center, randomized, partially-blinded, Phase II, small, targeted, prospective study in approximately 30 healthy male and non-pregnant female subjects aged 18 to 49 years o...

H7N9 Boost in Healthy Adults

The study will be an open-label phase 2 clinical trial of a single dose of an inactivated H7N9 vaccine (non-adjuvanted). The subjects of the study will be individuals who previously partic...

Reactogenicity, Safety and Immunogenicity of a LAIV H7N9 Influenza Vaccine

This is a single centre phase I, double-blind placebo-controlled study to assess reactogenicity, safety and immunogenicity of a live monovalent A/17/Anhui/2013/61 (H7N9) influenza vaccine ...

H7N9 Mix and Match With MF59 in Healthy Elderly Persons

This is a Phase II randomized, partially-blinded, controlled trial in 360 (up to 600) males and females, 65 years of age and older, who are in good health and meet all eligibility criteria...

A Study to Evaluate the Safety and Immunogenicity of H7N9 Influenza Vaccine (AT-501) in Healthy Adult Subjects

This study aims to evaluate the safety and immunogenicity of an inactivated cell culture derived H7N9 vaccine in healthy adult subjects.

H7 Influenza Prime-Boost Regimens in Healthy Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or With Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime With MIV Boost Compared to MIV Prime With MIV Boo...

Background:< TAB> - Flu virus that causes disease in birds can sometimes spread to people. It can cause severe illness, even death. Vaccines are used to try to create resistance to such i...

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age

The purpose of this study is to evaluate the safety and immunogenicity of different formulations of GSK Biologicals' H7N9 influenza vaccine in subjects 18 to 64 years of age.

H7N9 Mix and Match With AS03 and MF59 in Healthy Adults

This Phase II randomized, double-blinded, controlled study in up to 1000 males and non-pregnant females, 19 to 64 years old, inclusive, who are in good health and meet all eligibility crit...

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3277510A and GSK3277509A in Adults 18 to 60 Years of Age

The purpose of this study is to evaluate the safety and immunogenicity of different formulations of GSK Biologicals' H7N9 influenza vaccine in subjects 18 to 60 years of age.

PubMed Articles [37 Associated PubMed Articles listed on BioPortfolio]

Highly Pathogenic Avian Influenza A(H7N9) Virus, Tennessee, USA, March 2017.

In March 2017, highly pathogenic avian influenza A(H7N9) was detected at 2 poultry farms in Tennessee, USA. Surveillance data and genetic analyses indicated multiple introductions of low pathogenicity...

Characteristics of the emerging chicken-origin highly pathogenic H7N9 viruses: a new threat to public health and poultry industry.

Two H7N9 chicken isolates showed amino acids insertion and mutation in the cleavage site of the hemagglutinin similar as those from the reported human cases. Phylogenetically, they formed a separate c...

Drug Susceptibility Evaluation of an Influenza A(H7N9) Virus by Analyzing Recombinant Neuraminidase Proteins.

Neuraminidase (NA) inhibitors are the recommended antiviral medications for influenza treatment. However, their therapeutic efficacy can be compromised by NA changes that emerge naturally and/or follo...

Commentary: A Historical Review of Centers for Disease Control and Prevention Antiviral Treatment and Postexposure Chemoprophylaxis Guidance for Human Infections With Novel Influenza A Viruses Associated With Severe Human Disease.

Human infections with novel influenza A viruses are of global public health concern, and antiviral medications have a potentially important role in treatment and prevention of human illness. Initial g...

Clusters of Human Infections With Avian Influenza A(H7N9) Virus in China, March 2013 to June 2015.

Multiple clusters of human infections with novel avian influenza A(H7N9) virus have occurred since the virus was first identified in spring 2013. However, in many situations it is unclear whether thes...

The Global Threat of Animal Influenza Viruses of Zoonotic Concern: Then and Now.

Animal influenza viruses can reassort or mutate to infect and spread sustainably among people and cause a devastating worldwide pandemic. Since the first evidence of human infection with an animal inf...

Highly conserved M2e and hemagglutinin epitope-based recombinant proteins induce protection against influenza virus infection.

Highly pathogenic influenza viruses continue to cause serious threat to public health due to their pandemic potential, calling for an urgent need to develop effective, safe, convenient, and universal ...

The role of nuclear NS1 protein in highly pathogenic H5N1 influenza viruses.

The non-structural protein (NS1) of influenza A viruses (IAV) performs multiple functions during viral infection. NS1 contains two nuclear localization signals (NLS): NLS1 and NLS2. The NS1 protein is...

Update: Increase in Human Infections with Novel Asian Lineage Avian Influenza A(H7N9) Viruses During the Fifth Epidemic - China, October 1, 2016-August 7, 2017.

Among all influenza viruses assessed using CDC's Influenza Risk Assessment Tool (IRAT), the Asian lineage avian influenza A(H7N9) virus (Asian H7N9), first reported in China in March 2013,* is ranked ...

Isolation and characterization of H4N6 avian influenza viruses from mallard ducks in Beijing, China.

The novel H7N9 influenza virus, which has caused severe disease in humans in China, is a reassortant with surface genes derived from influenza viruses in wild birds. This highlights the importance of ...

Videos

None available.

Medical and Biotech [MESH] Definitions

A subtype of INFLUENZA A VIRUS with the surface proteins hemagglutinin 7 and neuraminidase 9. This avian origin virus was first identified in humans in 2013.

Quick Search
Advertisement
 

Relevant Topics

Influenza
Influenza or 'flu' is a respiratory illness associated with infection by influenza virus. Symptoms frequently include headache, fever, cough, sore throat, aching muscles and joints. There is a wide spectrum of severity of illness ranging from min...

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...

Swine Flu - H1N1 influenza - H7N9
Swine flu is the common name given to a relatively new strain of influenza (flu) that caused a flu pandemic in 2009-2010. It is also referred to as H1N1 influenza (because it is the H1N1 strain of virus). The H1N1 flu virus will be one of the main vi...

review and buy H7N9 Bird Flu Virus market research data and corporate reports here

Channels Quicklinks